1h Free Analyst Time
The renal anemia therapeutics market is forecasted to grow by USD 3.35 billion during 2024-2029, accelerating at a CAGR of 9% during the forecast period. The report on the renal anemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by presence of large pool of ckd patients, growing geriatric population, and new drug approvals for renal anemia therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The renal anemia therapeutics market is segmented as below:
By Type
- IV
- Oral
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Form Factor
- Solid
- Liquid
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the renal anemia therapeutics market covers the following areas:
- Renal Anemia Therapeutics Market sizing
- Renal Anemia Therapeutics Market forecast
- Renal Anemia Therapeutics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Distribution Channel
10 Market Segmentation by Form Factor
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global renal anemia therapeutics market: Akebia Therapeutics, Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, CSL Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., GlaxoSmithKline Plc, Japan Tobacco Inc., JCR Pharmaceticals Co. Ltd., Kirin Holdings Co. Ltd., Mitsubishi Chemical Group Corp., Pfizer Inc., Pharmacosmos AS, Sun Pharmaceutical Industries Ltd., and Travere Therapeutics Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing adoption of biosimilars."
According to the report, one of the major drivers for this market is the presence of large pool of ckd patients.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akebia Therapeutics
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- CSL Ltd.
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- GlaxoSmithKline Plc
- Japan Tobacco Inc.
- JCR Pharmaceticals Co. Ltd.
- Kirin Holdings Co. Ltd.
- Mitsubishi Chemical Group Corp.
- Pfizer Inc.
- Pharmacosmos AS
- Sun Pharmaceutical Industries Ltd.
- Travere Therapeutics Inc.
